T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy DOI Creative Commons

Zhanyan Gao,

Yang Feng, Jinhua Xu

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Sept. 23, 2022

Immune-mediated inflammatory diseases(IMIDs) are referred to as highly disabling chronic diseases affecting different organs and systems. Inappropriate or excessive immune responses with inflammation typical manifestations. Usually in patients infection cancer, due long-term exposure persistent antigens microenvironment, T-cells continuously stimulated gradually differentiate into an exhausted state. Exhausted lose effector function characteristics of memory T-cells. However, existing studies have found that not only present the tumor environment, but also autoimmunity, associated better prognosis IMIDs. This suggests new prospects for application this reversible process T-cell exhaustion treatment IMID. review will focus on research progress several IMIDs its potential diagnosis

Language: Английский

An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus DOI
Beidi Chen, Xinmiao Jia,

Jia‐yue Xu

et al.

Arthritis & Rheumatology, Journal Year: 2020, Volume and Issue: 73(2), P. 232 - 243

Published: Oct. 30, 2020

Objective Changes in gut microbiota have been linked to systemic lupus erythematosus (SLE), but knowledge is limited. Our study aimed provide an in‐depth understanding of the contribution immunopathogenesis SLE. Methods Fecal metagenomes from 117 patients with untreated SLE and 52 posttreatment were aligned 115 matched healthy controls analyzed by whole‐genome profiling. For comparison, we assessed fecal metagenome MRL/ lpr mice. The oral origin species that existed was documented single‐nucleotide polymorphism–based strain‐level analyses. Functional validation assays performed demonstrate molecular mimicry newly found microbial peptides. Results Gut individuals displayed significant differences composition function compared controls. Certain species, including Clostridium ATCC BAA‐442 as well Atopobium rimae , Shuttleworthia satelles Actinomyces massiliensis Bacteroides fragilis leptum enriched reduced after treatment. Enhanced lipopolysaccharide biosynthesis branched chain amino acid observed patients. findings mice consistent our human subjects. Interestingly, some demonstrated proinflammatory capacities peptides derived SLE‐enriched species. Conclusion This provides detailed information on SLE, their functional signatures, similarities murine counterparts, origin, definition autoantigen‐mimicking data microbiome‐altering approaches may offer valuable adjuvant therapies

Language: Английский

Citations

172

Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases DOI Creative Commons

Hanna Graßhoff,

Sara Comdühr,

Luisa R. Monne

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: April 1, 2021

Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and control ongoing inflammation autoimmunity. The cytokine interleukin-2 (IL-2) is essentially required growth survival Treg in lymphatic tissues thus plays a vital role biology Treg. Most autoimmune rheumatic diseases exhibit disturbances either at numerical or functional level resulting an imbalance between protective pathogenic immune cells. In addition, some diseases, relative deficiency IL-2 develops during disease pathogenesis leading to disturbance homeostasis, which further amplifies vicious cycle breach chronic inflammation. Low-dose therapy aims compensate this restore physiological state strengthen population order be more effective counter-regulating while avoiding global immunosuppression. Here we highlight key findings summarize recent advances clinical translation low-dose treatment diseases.

Language: Английский

Citations

122

Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies DOI Creative Commons
Hao Li,

Afroditi Boulougoura,

Yushiro Endo

et al.

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 132, P. 102870 - 102870

Published: July 22, 2022

Language: Английский

Citations

115

Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial DOI
Cancan Huang, Ping Yi,

Zhu Ming

et al.

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 130, P. 102844 - 102844

Published: June 1, 2022

Language: Английский

Citations

91

Pyroptosis and Its Role in Autoimmune Disease: A Potential Therapeutic Target DOI Creative Commons
Ruixuan You,

Xinglan He,

Zhuotong Zeng

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: May 25, 2022

Autoimmune diseases are a group of heterogeneous with diverse clinical manifestations that can be divided into systemic and organ-specific. The common etiology autoimmune is the destruction immune tolerance production autoantibodies, which attack specific tissues and/or organs in body. pathogenesis complicated, genetic, environmental, infectious, even psychological factors work together to cause aberrant innate adaptive responses. Although exact mechanisms unclear, recently, excessive exacerbation pyroptosis, as bond between immunity, has been proven play crucial role development disease. Pyroptosis characterized by pore formation on cell membranes, well rupture excretion intracellular contents pro-inflammatory cytokines, such IL-1β IL-18. This overactive inflammatory programmed death disrupts system homeostasis promotes autoimmunity. review examines molecular structure classical inflammasomes, including NLRP3, AIM2, P2X7-NLRP3, switches their regulation mechanisms. sophisticated pyroptosis pathways, canonical caspase-1-mediated pathway, noncanonical caspase-4/5/11-mediated emerging caspase-3-mediated caspase-independent also described. We highlight recent advances diseases, lupus erythematosus, rheumatoid arthritis, bowel disease, Sjögren’s syndrome dermatomyositis, attempt identify its potential advantages therapeutic target or prognostic marker these diseases.

Language: Английский

Citations

84

Autoimmune pre-disease DOI
Katja Bieber, Jennifer E. Hundt, Xinhua Yu

et al.

Autoimmunity Reviews, Journal Year: 2022, Volume and Issue: 22(2), P. 103236 - 103236

Published: Nov. 25, 2022

Language: Английский

Citations

79

Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming DOI Creative Commons
Kuniyuki Aso, Michihito Kono, Masatoshi Kanda

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Feb. 27, 2023

Abstract Dysregulation of Th17 and Treg cells contributes to the pathophysiology many autoimmune diseases. Herein, we show that itaconate, an immunomodulatory metabolite, inhibits cell differentiation promotes by orchestrating metabolic epigenetic reprogramming. Mechanistically, itaconate suppresses glycolysis oxidative phosphorylation in Th17- Treg-polarizing T cells. Following treatment with S-adenosyl-L-methionine/S-adenosylhomocysteine ratio 2-hydroxyglutarate levels are decreased inhibiting synthetic enzyme activities cells, respectively. Consequently, these changes associated altered chromatin accessibility essential transcription factors key gene expression differentiation, including RORγt binding at Il17a promoter. The adoptive transfer itaconate-treated Th17-polarizing ameliorates experimental encephalomyelitis. These results indicate is a crucial regulator for Th17/Treg balance could be potential therapeutic agent

Language: Английский

Citations

79

Stimulus‐Responsive Hydrogels as Drug Delivery Systems for Inflammation Targeted Therapy DOI Creative Commons
Haoyu Yu,

Rong-Yao Gao,

Yuxin Liu

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 11(1)

Published: Nov. 20, 2023

Abstract Deregulated inflammations induced by various factors are one of the most common diseases in people's daily life, while severe inflammation can even lead to death. Thus, efficient treatment has always been hot topic research medicine. In past decades, as a potential biomaterial, stimuli‐responsive hydrogels have focus attention for due their excellent biocompatibility and design flexibility. Recently, thanks rapid development nanotechnology material science, more efforts made develop safer, personal effective therapy some frequent but tough such sepsis, rheumatoid arthritis, osteoarthritis, periodontitis, ulcerative colitis. Herein, from recent studies articles, conventional emerging delivery anti‐inflammatory drugs summarized. And prospects clinical translation future also discussed further detail.

Language: Английский

Citations

52

Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus DOI Creative Commons
Matteo Doglio, Alessio Ugolini,

Clara Bercher-Brayer

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: March 27, 2024

Abstract Systemic Lupus Erythematosus (SLE) is a progressive disease leading to immune-mediated tissue damage, associated with an alteration of lymphoid organs. Therapeutic strategies involving regulatory T (Treg) lymphocytes, which physiologically quench autoimmunity and support long-term immune tolerance, are considered, as conventional treatment often fails. We describe here therapeutic strategy based on Tregs overexpressing FoxP3 harboring anti-CD19 CAR (Fox19CAR-Tregs). Fox19CAR-Tregs efficiently suppress proliferation activity B cells in vitro, relevant for SLE pathogenesis. In humanized mouse model SLE, single infusion restricts autoantibody generation, delay lymphopenia (a key feature SLE) restore the human system composition organs, without detectable toxicity. Although short survival, target organs appear be protected. summary, can break vicious cycle persistent representing efficacious safe allowing restoration homeostasis SLE.

Language: Английский

Citations

30

The immunology of systemic lupus erythematosus DOI
George C. Tsokos

Nature Immunology, Journal Year: 2024, Volume and Issue: 25(8), P. 1332 - 1343

Published: July 15, 2024

Language: Английский

Citations

28